Thoratec (NSDQ:THOR) landed FDA approval to launch a new study evaluating its HeartMate II ventricular assist system in a less-sick class of patients.
J.P. Morgan Healthcare Conference
MassDevice.com Q&A: Medtronic CEO Omar Ishrak
Just a few days into his tenure as CEO of Medtronic (NYSE:MDT), Omar Ishrak was confronted with a major crisis: The Spine Journal devoted its entire June issue to to exposing problems with growth proteins, including a repudiation of some of the research surrounding Infuse.
Abbott CFO details post-spinout medical products biz
Medical devices will contribute about 27% of Abbott’s (NYSE:ABT) sales after it spins out its research pharmaceuticals unit later this year, CFO Thomas Freyman said today at the J.P. Morgan health care conference in San Francisco.
Abbott announced its plan to split into two publicly traded companies late last year, creating a new entity for the research pharma unit and keeping the Abbott name for the remaining medical products businesses.
MassDevice.com +3: The JP Morgan conference edition | Meet Medtronic’s Omar Ishrak, Covidien CEO talks ev3 and Thoratec gears up to compete with Abiomed
Say hello to a special edition of MassDevice +3, a bite-sized view of the top three med-tech stories coming out of the JP Morgan health care conference in San Francisco. Stay tuned the rest of this week for more breaking medical device news!
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Thoratec gears up to compete with Abiomed
Pleasanton, Calif.-based Thoratec is getting into the ring with Abiomed (NSDQ:ABMD), preparing its version of a percutaneous heart pump to compete with the Impella device that Abiomed already has on the market, CEO Gary Burbach said at the JP Morgan health care conference this morning.
Meet the new boss: Medtronic CEO Ishrak lays out priorities
After 7 months on the job, Medtronic CEO Omar Ishrak laid out his vision for transforming the world’s largest pure-play medical device maker today at his first appearance at the J.P. Morgan health care comference in San Francisco.
Covidien CEO: ev3 Pipeline is taking off across the globe
The Pipeline stroke-treatment device Covidien plc (NYSE:COV) acquired with its $2.6 billion acquisition of ev3 Inc. is gaining share in markets across the globe, CEO Jose Almeida told analysts this morning.
Covidien’s acquisition of ev3 is paying off around the world and is expected to do "slightly better" than originally thought, Almeida told investors at the JP Morgan health care conference in San Francisco today.